First-Ever trial targets dangerous weight gain from essential meds in overlooked population
NCT ID NCT05744479
Summary
This study is testing whether the common diabetes drug metformin can help adults with intellectual disabilities lose weight they've gained from taking necessary antipsychotic medications. It's the first randomized trial specifically for this underserved group, who face high rates of obesity and related health problems but are often excluded from research. Over 24 weeks, researchers will compare weight changes and metabolic health in 100 participants taking either metformin or a placebo pill.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre for Addiction and Mental Health
RECRUITINGToronto, Ontario, M6J1H3, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.